News
BIVI
1.130
-5.04%
-0.060
BioVie Stockholders Approve Directors, Auditor, and Equity Plan
TipRanks · 3d ago
BioVie Reports Distinct Biomarker Responses In Phase 2 Long COVID Trial; Stock Down
NASDAQ · 4d ago
BioVie presents new biomarker data from ADDRESS-LC trial of bezisterim
TipRanks · 4d ago
BioVie Presents New Biomarker Data From ADDRESS-LC Trial Of Bezisterim In Long COVID; Analyses Suggest Single Efficacy Endpoint May Not Adequately Capture Clinically Meaningful Response To Therapeutic Intervention Across Biological Diversity Of Long Covid
Benzinga · 4d ago
Weekly Report: what happened at BIVI last week (1102-1106)?
Weekly Report · 4d ago
Fusion Power, Global Capital, Branded Streaming and Neurology Breakthroughs: New to The Street Show #779 Premieres Tonight on Bloomberg Television
Barchart · 6d ago
BioVie Inc. Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement
NASDAQ · 6d ago
BioVie Closes $4.74 Million Registered Direct Offering
TipRanks · 11/06 22:30
BioVie Announces $4.74 Mln Registered Direct Offering; Shares Fall 26%
NASDAQ · 11/04 18:38
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 11/04 17:05
BioVie launches $4.74M direct offering and concurrent private placement
Seeking Alpha · 11/04 13:39
BioVie Announces $4.74M Registered Direct Offering And Concurrent Private Placement
Benzinga · 11/04 13:06
Press Release: BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Dow Jones · 11/04 13:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 11/03 17:05
BioVie Invited To Present Late-Breaking Oral Presentation At The 4th Long Covid International Conference, November 12-13
Benzinga · 11/02 14:02
Weekly Report: what happened at BIVI last week (1026-1030)?
Weekly Report · 11/02 09:28
From Global Private Credit to Programmable Securities: New to The Street Show #778 Premieres Tonight on Bloomberg Television
Barchart · 10/31 10:00
Weekly Report: what happened at BIVI last week (1019-1023)?
Weekly Report · 10/26 09:28
From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television
Barchart · 10/24 09:30
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 10/20 17:05
More
Webull provides a variety of real-time BIVI stock news. You can receive the latest news about Biovie Inc through multiple platforms. This information may help you make smarter investment decisions.
About BIVI
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.